Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001599298-25-000025
Filing Date
2025-01-06
Accepted
2025-01-06 19:11:22
Documents
4
Period of Report
2025-01-02

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1736208674.html 4  
1 FORM 4 wk-form4_1736208674.xml 4 4103
2 EX-24 poasec16-mostafaronaghif.htm EX-24 5160
3 GRAPHIC poasec16-mostafaronaghif001.jpg GRAPHIC 274112
4 poasec16-mostafaronaghif002.jpg GRAPHIC 35234
  Complete submission text file 0001599298-25-000025.txt   437171
Mailing Address 9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
Business Address
Ronaghi Mostafa (Reporting) CIK: 0001441876 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36866 | Film No.: 25512943

Mailing Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131
Business Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 305-203-2034
Summit Therapeutics Inc. (Issuer) CIK: 0001599298 (see all company filings)

EIN.: 371979717 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)